Alkem Laboratories Ltd's Q4FY25 Quarter Results
- 30 May 2025
Result Summary
- Alkem Laboratories Ltd reported a 12.8% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 1.8%.
- Its expenses for the quarter were down by 3.4% QoQ and 0.5% YoY.
- The net profit decreased 52.5% QoQ and increased 349.9% YoY.
- The earnings per share (EPS) of Alkem Laboratories Ltd stood at 24.6 during Q4FY25.
Financial Statments for Q4FY25
| (₹ crores) | Q4FY25 | Q3FY25 | Q4FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 3023.99 | 3467.27 | 2971.27 | -12.8% | 1.8% |
Total Expenses | 2644.13 | 2736.20 | 2656.63 | -3.4% | -0.5% |
Profit Before Tax | 367.34 | 731.07 | 211.66 | -49.8% | 73.6% |
Tax | 62.86 | 90.28 | 143.98 | -30.4% | -56.3% |
Profit After Tax | 304.48 | 640.79 | 67.68 | -52.5% | 349.9% |
Earnings Per Share | 24.60 | 52.30 | 5.90 | -53.0% | 316.9% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Alkem Laboratories Ltd is a prominent player in the pharmaceutical industry, primarily involved in the development, manufacturing, and marketing of pharmaceutical formulations and nutraceuticals. The company's portfolio includes a diverse range of therapeutic segments such as anti-infectives, gastroenterology, pain management, and dermatology. Alkem has a significant presence in both the domestic and international markets, with a strong emphasis on research and development to innovate and enhance their product offerings. In recent times, the company has been focusing on expanding its global footprint and increasing its market share through strategic partnerships and acquisitions.
Revenue
Alkem Laboratories Ltd reported a total income of ₹3,023.99 crores in Q4FY25, marking a decrease from ₹3,467.27 crores in Q3FY25, reflecting a quarter-over-quarter decline of 12.8%. Compared to Q4FY24, where the total income was ₹2,971.27 crores, there is a year-over-year increase of 1.8%. This data indicates a fluctuation in the revenue stream over the quarters but shows a steady upward trend compared to the previous year. The decrease in total income QoQ could be attributed to seasonal variations or market conditions affecting the sales volume.
Profitability
The profitability of Alkem Laboratories Ltd has experienced notable changes over the period under review. The profit before tax for Q4FY25 stands at ₹367.34 crores, which is a significant drop from ₹731.07 crores recorded in Q3FY25, indicating a QoQ decline of 49.8%. However, when comparing Q4FY25 to Q4FY24, where the profit before tax was ₹211.66 crores, there is a substantial YoY increase of 73.6%. The profit after tax for Q4FY25 is reported at ₹304.48 crores, a decrease from ₹640.79 crores in Q3FY25, reflecting a QoQ reduction of 52.5%. In contrast, compared to Q4FY24's profit after tax of ₹67.68 crores, there is a significant YoY increase of 349.9%. The earnings per share have also shown a similar pattern, decreasing from ₹52.30 in Q3FY25 to ₹24.60 in Q4FY25, yet showing a dramatic improvement from ₹5.90 in Q4FY24.
Operating Metrics
The company’s total expenses for Q4FY25 are reported at ₹2,644.13 crores, which is a decrease from the ₹2,736.20 crores incurred in Q3FY25, showing a QoQ decline of 3.4%. When compared to Q4FY24, where the total expenses were ₹2,656.63 crores, there is a slight YoY decrease of 0.5%. The tax expense for Q4FY25 amounts to ₹62.86 crores, down from ₹90.28 crores in Q3FY25, marking a 30.4% reduction QoQ. This is also significantly lower than the tax expense of ₹143.98 crores in Q4FY24, reflecting a YoY reduction of 56.3%. These figures suggest a strategic management of operational costs and tax liabilities, which could contribute to the overall financial health of the company.